GPCR - Structure Therapeutics Inc Profit before interest, taxes and amortization
Structure Therapeutics (GPCR) price action is exposed to the risk of clinical failures and intense pressure from leaders in the metabolic drug market. The EBITDA distribution by period demonstrates that the metric is fixed at 0.00. The business relies on production outsourcing via CMOs and attracts leading endocrinologists through stock option programs, which stabilizes the company's internal potential during the development of new drugs.
Summary analytical data breakdowns for Structure Therapeutics Inc. (GPCR)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization data:
- company total debt and liquidity indicators:
Debt to Equity Structure Therapeutics|GPCR - Long-Term Debt to Equity|Current Liabilities to Capital Structure Therapeutics Inc|GPCR - Company Debts|Debt to Book Capitalization Ratio Structure Therapeutics|GPCR - Company Long-Term Debts|Short-Term Debt Volume Structure Therapeutics|Interim Coverage Ratio structuretx.com
- financial results and valuation multiples details:
GPCR - Company Net Income|Future Profit Structure Therapeutics|GPCR - Price to Earnings Ratio|Market Cap to Projected Earnings structuretx.com|GPCR - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Structure Therapeutics|GPCR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Structure Therapeutics|GPCR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth structuretx.com|GPCR - Earnings growth in current year|Expected earnings per share growth for next year Structure Therapeutics
Analysis of all company metrics:Structure Corp (GPCR)
This indicator reflects the daily net cash flow from the company's core operations. By analyzing absolute operating profit, an investor determines the business's actual ability to act as a cash generator. The metric is sensitive to operating expenses and excludes the impact of leverage. For the biotech startup Structure Therapeutics (GPCR), it captures R&D costs. Low environmental costs and conservative waste utilization minimize unplanned write-offs within this metric.
Who Structure Therapeutics competes with
ASND - Operating profit before deduction of amortization|Madrigal Pharmaceuticals - Operating profit EBITDA|Profit before interest, taxes and amortization corcept.com|RYTM (Rhythm Pharmaceuticals, Inc.) - Operating profit before deduction of amortization|AKRO: Company profit before taxes, interest and amortization|MTSR (Metsera Corp) - Operating profit EBITDA|Operating profit EBITDA MoonLake Corp|Operating profit EBITDA CRNX|Profit before payment of interest, taxes and amortization NAMS (newamsterdampharma.com)|Profit before payment of interest, taxes and amortization Soleno Therapeutics, Inc. SLNO|Amicus Therapeutics Inc (FOLD) - Profit before interest, taxes and amortization|ETNB - Profit before payment of interest, taxes and amortization|AGIO: Profit before payment of interest, taxes and amortization|MDXG: Operating profit EBITDA|RZLT - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Altimmune Corp (ALT)|Operating profit before deduction of amortization Aardvark Pharma AARD|Profit before payment of interest, taxes and amortization Sagimet Biosciences SGMT|Operating income before deduction of amortization bioagelabs.com (BIOA)|BMEA: Operating profit before deduction of amortization|Quince Therapeutics - Company profit before taxes, interest and amortization|Fractyl (GUTS) - Profit before payment of interest, taxes and amortization|vTv Therapeutics - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization ATPC|Operating profit EBITDA Pluri Inc|Operating profit EBITDA SYBX|Operating profit before deduction of amortization Lipocine Inc LPCN|Matinas BioPharma Holdings - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization SPRB (sprucebiosciences.com)|GLTO: Operating profit before deduction of amortization|CTCX - Operating profit EBITDA|Lumos Pharma (LUMO) - Profit before payment of interest, taxes and amortization|Organovo Holdings - Income before deduction of interest, taxes and amortization|RDUS (Radius Health) - Operating profit EBITDA
